The COPCOV Trial’s position statement on “A living WHO guideline on drugs to prevent COVID-19.”
Following WHO recommendations against the use of hydroxychloroquine in the prevention of COVID-19, including its use in controlled trials, we are reviewing the guideline and available evidence. We are concerned that this judgement from the authors of the guideline is scientifically unsound.
T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses.
Ogbe A. et al, (2021), Nature communications, 12
Improving Treatment and Outcomes for Melioidosis in Children, Northern Cambodia, 2009-2018.
Chandna A. et al, (2021), Emerg Infect Dis, 27, 1169 - 1172
SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)
Hall VJ. et al, (2021), The Lancet